{"pmid":32466458,"title":"Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.","text":["Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.","The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, accurate, and rapid diagnostic technologies to contain emerging and re-emerging pandemics. Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) based assays performed on respiratory specimens remain the gold standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging with high sensitivity and specificity as well. Even though excellent techniques are available for the diagnosis of symptomatic patients with COVID-19 in well-equipped laboratories; critical gaps still remain in screening asymptomatic people who are in the incubation phase of the virus, as well as in the accurate determination of live viral shedding during convalescence to inform decisions for ending isolation. This review article aims to discuss the currently available laboratory methods and surveillance technologies available for the detection of COVID-19, their performance characteristics and highlight the gaps in current diagnostic capacity, and finally, propose potential solutions. We also summarize the specifications of the majority of the available commercial kits (PCR, EIA, and POC) for laboratory diagnosis of COVID-19.","Viruses","Younes, Nadin","Al-Sadeq, Duaa W","Al-Jighefee, Hadeel","Younes, Salma","Al-Jamal, Ola","Daas, Hanin I","Yassine, Hadi M","Nasrallah, Gheyath K","32466458"],"abstract":["The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, accurate, and rapid diagnostic technologies to contain emerging and re-emerging pandemics. Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) based assays performed on respiratory specimens remain the gold standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging with high sensitivity and specificity as well. Even though excellent techniques are available for the diagnosis of symptomatic patients with COVID-19 in well-equipped laboratories; critical gaps still remain in screening asymptomatic people who are in the incubation phase of the virus, as well as in the accurate determination of live viral shedding during convalescence to inform decisions for ending isolation. This review article aims to discuss the currently available laboratory methods and surveillance technologies available for the detection of COVID-19, their performance characteristics and highlight the gaps in current diagnostic capacity, and finally, propose potential solutions. We also summarize the specifications of the majority of the available commercial kits (PCR, EIA, and POC) for laboratory diagnosis of COVID-19."],"journal":"Viruses","authors":["Younes, Nadin","Al-Sadeq, Duaa W","Al-Jighefee, Hadeel","Younes, Salma","Al-Jamal, Ola","Daas, Hanin I","Yassine, Hadi M","Nasrallah, Gheyath K"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32466458","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/v12060582","keywords":["covid-19","sars-cov-2","diagnostic challenges","molecular testing","serology","viruses"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1668420887292936193,"score":9.490897,"similar":[{"pmid":32282894,"pmcid":"PMC7170415","title":"Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review.","text":["Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review.","Diagnostic testing to identify persons infected with severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-19 that began in late 2019. In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies. In contrast, the United States, hampered by limited testing capacity, has prioritized testing for specific groups of persons. Real-time reverse transcriptase polymerase chain reaction-based assays performed in a laboratory on respiratory specimens are the reference standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging. Although excellent tools exist for the diagnosis of symptomatic patients in well-equipped laboratories, important gaps remain in screening asymptomatic persons in the incubation phase, as well as in the accurate determination of live viral shedding during convalescence to inform decisions to end isolation. Many affluent countries have encountered challenges in test delivery and specimen collection that have inhibited rapid increases in testing capacity. These challenges may be even greater in low-resource settings. Urgent clinical and public health needs currently drive an unprecedented global effort to increase testing capacity for SARS-CoV-2 infection. Here, the authors review the current array of tests for SARS-CoV-2, highlight gaps in current diagnostic capacity, and propose potential solutions.","Ann Intern Med","Cheng, Matthew P","Papenburg, Jesse","Desjardins, Michael","Kanjilal, Sanjat","Quach, Caroline","Libman, Michael","Dittrich, Sabine","Yansouni, Cedric P","32282894"],"abstract":["Diagnostic testing to identify persons infected with severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-19 that began in late 2019. In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies. In contrast, the United States, hampered by limited testing capacity, has prioritized testing for specific groups of persons. Real-time reverse transcriptase polymerase chain reaction-based assays performed in a laboratory on respiratory specimens are the reference standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging. Although excellent tools exist for the diagnosis of symptomatic patients in well-equipped laboratories, important gaps remain in screening asymptomatic persons in the incubation phase, as well as in the accurate determination of live viral shedding during convalescence to inform decisions to end isolation. Many affluent countries have encountered challenges in test delivery and specimen collection that have inhibited rapid increases in testing capacity. These challenges may be even greater in low-resource settings. Urgent clinical and public health needs currently drive an unprecedented global effort to increase testing capacity for SARS-CoV-2 infection. Here, the authors review the current array of tests for SARS-CoV-2, highlight gaps in current diagnostic capacity, and propose potential solutions."],"journal":"Ann Intern Med","authors":["Cheng, Matthew P","Papenburg, Jesse","Desjardins, Michael","Kanjilal, Sanjat","Quach, Caroline","Libman, Michael","Dittrich, Sabine","Yansouni, Cedric P"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282894","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.7326/M20-1301","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491459731457,"score":373.87125},{"pmid":32196430,"pmcid":"PMC7172701","title":"Laboratory diagnosis of emerging human coronavirus infections - the state of the art.","text":["Laboratory diagnosis of emerging human coronavirus infections - the state of the art.","The three unprecedented outbreaks of emerging human coronavirus (HCoV) infections at the beginning of the twenty-first century have highlighted the necessity for readily available, accurate and fast diagnostic testing methods. The laboratory diagnostic methods for human coronavirus infections have evolved substantially, with the development of novel assays as well as the availability of updated tests for emerging ones. Newer laboratory methods are fast, highly sensitive and specific, and are gradually replacing the conventional gold standards. This presentation reviews the current laboratory methods available for testing coronaviruses by focusing on the coronavirus disease 2019 (COVID-19) outbreak going on in Wuhan. Viral pneumonias typically do not result in the production of purulent sputum. Thus, a nasopharyngeal swab is usually the collection method used to obtain a specimen for testing. Nasopharyngeal specimens may miss some infections; a deeper specimen may need to be obtained by bronchoscopy. Alternatively, repeated testing can be used because over time, the likelihood of the SARS-CoV-2 being present in the nasopharynx increases. Several integrated, random-access, point-of-care molecular devices are currently under development for fast and accurate diagnosis of SARS-CoV-2 infections. These assays are simple, fast and safe and can be used in the local hospitals and clinics bearing the burden of identifying and treating patients.","Emerg Microbes Infect","Loeffelholz, Michael J","Tang, Yi-Wei","32196430"],"abstract":["The three unprecedented outbreaks of emerging human coronavirus (HCoV) infections at the beginning of the twenty-first century have highlighted the necessity for readily available, accurate and fast diagnostic testing methods. The laboratory diagnostic methods for human coronavirus infections have evolved substantially, with the development of novel assays as well as the availability of updated tests for emerging ones. Newer laboratory methods are fast, highly sensitive and specific, and are gradually replacing the conventional gold standards. This presentation reviews the current laboratory methods available for testing coronaviruses by focusing on the coronavirus disease 2019 (COVID-19) outbreak going on in Wuhan. Viral pneumonias typically do not result in the production of purulent sputum. Thus, a nasopharyngeal swab is usually the collection method used to obtain a specimen for testing. Nasopharyngeal specimens may miss some infections; a deeper specimen may need to be obtained by bronchoscopy. Alternatively, repeated testing can be used because over time, the likelihood of the SARS-CoV-2 being present in the nasopharynx increases. Several integrated, random-access, point-of-care molecular devices are currently under development for fast and accurate diagnosis of SARS-CoV-2 infections. These assays are simple, fast and safe and can be used in the local hospitals and clinics bearing the burden of identifying and treating patients."],"journal":"Emerg Microbes Infect","authors":["Loeffelholz, Michael J","Tang, Yi-Wei"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196430","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1080/22221751.2020.1745095","keywords":["covid-19","human coronavirus","poct","sars-cov-2","real-time pcr","serology"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138490038910978,"score":345.22284},{"pmid":32367615,"title":"Trends and innovations in biosensors for COVID-19 mass testing.","text":["Trends and innovations in biosensors for COVID-19 mass testing.","Fast and widespread diagnosis is crucial to fight against the outbreak of COVID-19. The present work surveys the landscape of available and emerging biosensor technologies for COVID-19 testing. Molecular diagnostic assays based on quantitative Reverse Transcription Polymerase Chain Reaction are used in most clinical laboratories. The COVID-19 pandemic has overwhelmed the testing capacity and motivated the development of fast point-of-care tests and the adoption of isothermal DNA amplification. Antigenic and serological rapid tests based on lateral flow immunoassays suffer from low sensitivity. Advanced digital systems enhance the performance at the expense of speed and large equipment requirement. Emerging technologies, including CRISPR gene-editing tools, benefit from high sensitivity and selectivity of molecular diagnostics and the easy use of lateral flow assays. DNA sequencing and sample pooling strategies are highlighted to bring out the full capacity of the available biosensor technologies and accelerate mass testing.","Chembiochem","Santiago, Ibon","32367615"],"abstract":["Fast and widespread diagnosis is crucial to fight against the outbreak of COVID-19. The present work surveys the landscape of available and emerging biosensor technologies for COVID-19 testing. Molecular diagnostic assays based on quantitative Reverse Transcription Polymerase Chain Reaction are used in most clinical laboratories. The COVID-19 pandemic has overwhelmed the testing capacity and motivated the development of fast point-of-care tests and the adoption of isothermal DNA amplification. Antigenic and serological rapid tests based on lateral flow immunoassays suffer from low sensitivity. Advanced digital systems enhance the performance at the expense of speed and large equipment requirement. Emerging technologies, including CRISPR gene-editing tools, benefit from high sensitivity and selectivity of molecular diagnostics and the easy use of lateral flow assays. DNA sequencing and sample pooling strategies are highlighted to bring out the full capacity of the available biosensor technologies and accelerate mass testing."],"journal":"Chembiochem","authors":["Santiago, Ibon"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367615","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/cbic.202000250","keywords":["covid-19","crispr diagnostics","immunoassays","isothermal amplification","molecular diagnostics"],"topics":["Diagnosis"],"weight":1,"_version_":1666138496268500992,"score":273.68353},{"pmid":32283141,"pmcid":"PMC7195339","title":"Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients.","text":["Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients.","An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nucleic acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative suspected cases was 43.6%. In addition, the concordance of whole blood samples and plasma showed Cohen's kappa value of 0.93, which represented the almost perfect agreement between two types of samples. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application.","J Infect","Pan, Yunbao","Li, Xinran","Yang, Gui","Fan, Junli","Tang, Yueting","Zhao, Jin","Long, Xinghua","Guo, Shuang","Zhao, Ziwu","Liu, Yinjuan","Hu, Hanning","Xue, Han","Li, Yirong","32283141"],"abstract":["An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nucleic acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative suspected cases was 43.6%. In addition, the concordance of whole blood samples and plasma showed Cohen's kappa value of 0.93, which represented the almost perfect agreement between two types of samples. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application."],"journal":"J Infect","authors":["Pan, Yunbao","Li, Xinran","Yang, Gui","Fan, Junli","Tang, Yueting","Zhao, Jin","Long, Xinghua","Guo, Shuang","Zhao, Ziwu","Liu, Yinjuan","Hu, Hanning","Xue, Han","Li, Yirong"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283141","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.03.051","keywords":["colloidal gold-based","covid-19","immunochromatographic strip","real-time rt-pcr","sars-cov-2","serology"],"locations":["Wuhan","China","ICG strip"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491462877186,"score":249.84108},{"pmid":32383182,"title":"Should RT-PCR be considered a gold standard in the diagnosis of Covid-19?","text":["Should RT-PCR be considered a gold standard in the diagnosis of Covid-19?","To face the new Covid-19 pandemic, the need for early and accurate diagnosis of the disease among suspected cases quickly became obvious for effective management, and for better control of the spread of the disease in the population. Since the beginning of this disease epidemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), reverse transcriptase polymerase chain reaction (RT-PCR) has routinely been used to confirm diagnosis. However, several authors have pointed out the poor performance of this technique, particularly in terms of sensitivity.(1,2) This article is protected by copyright. All rights reserved.","J Med Virol","Drame, Moustapha","Teguo, Maturin Tabue","Proye, Emeline","Hequet, Fanny","Hentzien, Maxime","Kanagaratnam, Lukshe","Godaert, Lidvine","32383182"],"abstract":["To face the new Covid-19 pandemic, the need for early and accurate diagnosis of the disease among suspected cases quickly became obvious for effective management, and for better control of the spread of the disease in the population. Since the beginning of this disease epidemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), reverse transcriptase polymerase chain reaction (RT-PCR) has routinely been used to confirm diagnosis. However, several authors have pointed out the poor performance of this technique, particularly in terms of sensitivity.(1,2) This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Drame, Moustapha","Teguo, Maturin Tabue","Proye, Emeline","Hequet, Fanny","Hentzien, Maxime","Kanagaratnam, Lukshe","Godaert, Lidvine"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383182","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25996","keywords":["covid-19","diagnosis","gold standard","rt-pcr","serology"],"topics":["Diagnosis"],"weight":1,"_version_":1666267276759793664,"score":244.71455}]}